Skip to content

Prader-Willi Syndrome Macronutrient Study

Evidence-Based Approach to Dietary Management of Prader-Willi Syndrome (PWS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02011360
Enrollment
10
Registered
2013-12-13
Start date
2014-05-31
Completion date
2016-05-31
Last updated
2016-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Obesity, Prader Willi Syndrome, Syndromic Obesity

Keywords

Prader Willi syndrome, childhood obesity, ghrelin, appetite regulation

Brief summary

The overall objective is to explore the mechanisms by which macronutrients regulate food intake and weight gain in Prader Willi Syndrome (PWS). Previous studies from the investigators' labs suggest that the increased appetite of PWS may be triggered or maintained by an increase in the levels of ghrelin, an appetite-stimulating hormone produced primarily by the stomach. This study will compare the effects of low carbohydrate diet versus low fat diet on levels of ghrelin, appetite suppressing hormones and markers of insulin sensitivity in patients with PWS. The investigators hypothesize that the low carbohydrate diet will suppress plasma active ghrelin and increase appetite-suppressing hormones to a greater degree and for longer duration than the low fat diet and will thereby reduce hyperphagia and increase satiety. The investigators also hypothesize that the low carb diet will improve hormonal and metabolic markers (fatty acids, amino acids and organic acids) of insulin sensitivity and inflammatory cytokine profiles of children with PWS.

Interventions

OTHERLow Carbohydrate diet

Low carbohydrate diet: 15%carb; 65%fat; 20% protein

OTHERLow Fat diet

Low Fat diet: 65%carb; 15%fat; 20% protein

Sponsors

Foundation for Prader-Willi Research
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of Prader Willi syndrome confirmed by chromosome analysis (ie. interstitial deletion of paternally-derived chromosome 15q, uniparental maternal disomy or other chromosome 15 abnormalities) * age 5 years to 17 years * written informed consent and assent obtained and willingness to comply with the study schedule and procedures * free T4, TSH values in the normal range (either endogenous or with thyroxine replacement) * weight stable (BMI percentile fluctuation of \<5 percentiles) over the preceding 2 months prior to the study

Exclusion criteria

* presence of other clinically significant disease that would impact body composition including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders * concomitant use of medications known to affect body weight or investigational drug in the past year

Design outcomes

Primary

MeasureTime frameDescription
Suppression of ghrelin10 hour fast following completion of dietary interventionFasting labs will be obtained immediately following dietary intervention. These labs will include total and active ghrelin.

Secondary

MeasureTime frameDescription
Changes in satietyDuring the 72 hour dietary interventionChanges in subjective hunger will be assessed by an appetite and hyperphagia questionnaire validated for PWS children. This will be completed by the children, with assistance of their parents, at completion of the 72 hour dietary intervention.
Improvements in insulin sensitivityDuring the 72 hour dietary intervention.The analysis will include measurements of adiponectin, GLP-1, glucose, insulin, AST, ALT, insulin sensitivity and a detailed profile (metabolomics) of amino acids, fatty acids, acylcarnitines, and adipocytokines on the day prior to and immediately following dietary intervention.

Other

MeasureTime frameDescription
Improvement in inflammatory cytokine profileDuring the 72 hour dietary interventionThe analysis will include measurements of adiponectin, GLP-1, glucose, insulin, AST, ALT, insulin sensitivity and a detailed profile (metabolomics) of amino acids, fatty acids, acylcarnitines, and adipocytokines on the day prior to and immediately following dietary intervention.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026